The Priority Review

Tag

Ascendis Pharma

1 story

  1. Clinical trials

    Ascendis Pharma registers Phase 3 trial of navepegritide and lonapegsomatropin in achondroplasia

    The study, led by Ascendis Pharma A/S, plans to enroll 144 participants and start in November 2026. It compares dual therapy with navepegritide and lonapegsomatropin to navepegritide monotherapy and lonapegsomatropin monotherapy in children and adolescents with achondroplasia.